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Abstract
The role of donor CMV serostatus in the setting of non T-cell depleted haplo-HSCT with post-transplant cyclophosphamide
(PT-Cy) has not been specifically addressed so far. Here we analyzed the impact of the donor CMV serological status on the
outcome of 983 CMV seropositive (CMV+), acute leukemia patients receiving a first, non T-cell depleted haplo-HSCT
registered in the EBMT database. The 1-year NRM was 21.3% (95% CI: 18.4–24.8) and 18.8% (95% CI: 13.8–25.5) in the
CMV D+/R+ and D−/R+ pairs, respectively (p= 0.40). Similarly, 1-year OS was 55.1% (95% CI: 50.1–58.0) and 55.7%
(95% CI: 48.0–62.8) in the same groups (p= 0.50). The other main outcomes were comparable. No difference in NRM nor
OS was observed after stratification for the intensity of conditioning and multivariate anaysis confirmed the lack of
significant association with NRM or OS. In conclusion, the choice of a CMV-seronegative donor did not impair early
survival of CMV-seropositive patients with acute leukemia after a first, non T-cell depleted haploidentical HSCT and PT-Cy
among this series of 983 consecutive patients. Future research may focus on the assessment of the hierarchy of all the donor
variables.
Introduction
CMV status is a major determinant of transplant outcome
[1–3] and it represents a key issue in the search for the
optimal donor. In a recent megafile analysis from the Eur-
opean Society for Blood and Marrow Transplantation
(EBMT) on almost 50,000 transplants [1] it was shown that
CMV-seronegative (CMV−) patients receiving CMV-
seropositive (CMV+) unrelated donor grafts had
decreased overall survival (OS) compared with CMV-
donors, but no difference was observed when the donor was
a HLA-identical sibling. The same analysis demonstrated
that CMV+ patients receiving grafts from CMV+ unrelated
donors had improved OS compared with CMV− donors
only if they had received myeloablative conditioning
(MAC). Thus, both the intensity of conditioning and the
type of donor modulate the impact of donor CMV ser-
ological status on the patient outcome [4, 5], the donor type
possibly through the type of immunosuppression and the
risk of associated graft-versus-host disease (GvHD). In
addition, the negative effects of CMV infection on patient
outcome might be amplified by the complications that may
occur after the administration of the currently available
antiviral drugs [6, 7].
While CMV serological status has been extensively
studied for both HLA-identical siblings and unrelated
donors, the significant worldwide increase in the use of
haploidentical transplantation [8] has not resulted in an
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increase of data about the impact of donor CMV status on
patient outcome, despite the fact that the availability of a
haploidentical family donor is generally greater than a
HLA-identical sibling, and multiple haploidentical donors
may be suitable for a single patient at the same time. CMV
reactivation rates after non T-cell depleted haploidentical
transplant range from 38 to 74% [9–13], contributing to the
infection-related toxicity associated with this platform.
Similarly, CMV disease is responsible for both morbidity
and mortality in the same setting. Due to the CMV-
associated toxicity and the greater availability of a haploi-
dentical family donor (virtually 100% of the parents and
offspring, 50% of siblings) compared with a HLA-identical
sibling, a better definition of the role of donor CMV ser-
ostatus on patients’ outcome after haploidentical transplan-
tation may help to improve the search for the optimal haplo-
donor. A recent analysis on 207 patient-donor pairs [14]
failed to demonstrate any significant clinical impact of
donor CMV serostatus after non T-cell depleted haploi-
dentical transplantation using high-dose post-transplant
cyclophosphamide (PT-Cy); however, it remains unknown
if this lack of effect was real or due to the relatively low
numbers in the series [14].
We thus conducted a registry-based analysis, on larger
numbers, with the aim of estimating the impact of donor
CMV serological status on the outcome of patients with
acute leukemia who received a non T-cell depleted hap-
loidentical transplantation and PT-Cy. Since a CMV- donor
is assumed to be the best choice for a CMV- patient, the
present analysis focuses on CMV+ patients only. However,
a descriptive analysis on the CMV-negative patients trans-
planted in the same period is also provided.
Patients and methods
The study was conducted on behalf of the Infectious Dis-
ease Working Party and the Acute Leukemia Working Party
of the EBMT. The EBMT is a voluntary working group of
more than 500 transplant centers, mostly located in Europe,
that are required to report all consecutive transplants and
follow-up data once a year. All the items in the present
analysis were collected through data retrieval from the
EBMT registry (Med-A forms) after the approval by both
Working Parties (WPs). No additional requests to centers
were made, except for the variable “donor age”,
whose coverage was 54% at the time of first statistical
analysis and reached 89% after the additional request.
Informed consent was obtained before the transplantation
procedure for all patients.
The inclusion criteria were: diagnosis of acute leukemia,
first allogeneic hematopoietic stem cell transplantation
(HSCT) performed from 1st January 2010 to 31st December
2015, patient CMV+ serological status, haploidentical
donor (defined as the presence of an “HLA-mismatched
relative” with “≥2 HLA loci mismatches”), GvHD prophy-
laxis including PT-Cy (defined as the presence of “cyclo-
phosphamide given after day 0” among the drugs given for
GvHD prophylaxis). The collected variables were as fol-
lows: donor CMV serological status, age, gender; patient
age, gender; disease, date of diagnosis, disease status at
HSCT; drugs and their cumulative doses administered
during the conditioning regimen, total body irradiation
(Yes/No and respective dose), intensity of conditioning
according to EBMT criteria, stem cell source, date of
infusion, other drugs in addition to PT-Cy administered for
GvHD prophylaxis, center activity (measured as the num-
bers of haplo-HSCT/year that are included in the analysis
from each center), neutrophil engraftment and date, acute
GvHD, grading and date, chronic GvHD, severity and date,
relapse date, death date, last follow-up, status and date,
cause of death.
Sample size definition
A previous reported experience [14] showed a 1-year non-
relapse mortality (NRM) of 24% and 31% in case of CMV
+ and CMV− donors, respectively for CMV+ patients.
Assuming that such a difference actually exists, and taking
into account the fact that more MAC regimens were
expected to be present in this series of only acute leukemia
compared to the previous one [14], a 50% increase in the
NRM difference, i.e., 11%, would represent a reasonable
and clinically meaningful difference to be detected, if pre-
sent, between the groups. Considering a two-sided alpha=
0.05 and a power= 0.80, our a priori calculation of sample
size led to a minimum of n= 700 patients needed to verify
this difference, meaning at least n= 525 and n= 175 in the
CMV+ and CMV− donor groups respectively, according
to an expected ratio of 3:1 [14]. These numbers were
obtained from the haploidentical HSCT activity in Europe,
therefore the analysis proved to be feasible and the study
was approved by both the IDWP and ALWP boards. Some
of the haplo-HSCTs reported in 2016 [14] are included in
the present analysis.
Statistical analysis
The main characteristics of patients were described report-
ing absolute and percentage frequencies in case of catego-
rical variables and median and range for the continuous
variables. Differences in the distribution between groups
(donor CMV+ vs. CMV−) have been verified by t-test or
U-Mann-Whitney test in case of continuous variables and
using chi-square or Fisher exact test in case of categorical
variables.
Donor CMV serostatus and haploidentical transplantation 423
NRM was estimated using the cumulative incidence
method, considering the relapse of the underlying disease as
competing event. A cause-specific Cox model was per-
formed in order to estimate the probability of NRM and OS
according to the donor CMV status; this model has been
adjusted by the main confounders taken into account, i.e.,
the variables resulted associated with the outcome of
interest with a p-value< 0.20 in univariate and p< 0.05 in
multivariate. Due to a potential distinct effect of donor
CMV serostatus according to the intensity of conditioning
[1], the possible interaction between the intensity of con-
ditioning regimen and the donor CMV serostatus was also
investigated. A post-hoc analysis was also performed,
investigating a potential interaction between the donor
CMV serostatus and the relationship between patient and
donor, this latter extrapolated from age difference (see
further).
Also progression-free survival, relapse-free survival,
incidence of acute and chronic GvHD, incidence of relapse
and of neutrophil engraftment were estimated together with
their respective 95% confidence interval (CI). The
Kaplan–Meier methods, Cox model and the cumulative
incidence methods were performed accordingly.
All the analyses were performed using the statistical
software SAS v. 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Demographics
A total of 983 CMV+ patients were identified, with a
median follow-up of 1.6 years from haplo-HSCT (95% CI:
1.4–1.8). Among these, n= 774 (79%) and n= 209 (21%)
had a CMV+ and CMV− donor, respectively (namely D
Table 1 Characteristics in the D+ /R+ and D−/R+ groups. In bold
are p-values <0.05.
CMV antibodies in donor Total
(N= 983)
p-value
CMV
seronegative
(N= 209)
CMV
seropositive
(N= 774)
N (%)
N (%) N (%)
Patient gender
Male 113 (54.1) 444 (57.4) 557 (56.7) Ns
Female 96 (45.9) 330 (42.6) 426 (43.3)
Donor gender
Male 129 (61.7) 434 (56.1) 563 (57.3) Ns
Female 80 (38.3) 340 (43.9) 420 (42.7)
Diagnosis
AML 160 (77.3) 537 (70.0) 697 (71.6) 0.07
ALL 43 (20.8) 220 (28.7) 263 (27.0)
Other 4 (1.9) 10 (1.3) 14 (1.4)
Disease stage at transplant
CR 126 (61.2) 516 (68.5) 642 (66.9) 0.047
no CR 80 (38.8) 237 (31.5) 317 (33.1)
Interval diagnosis to HSCT (months)
Median 7.7 8.3 8.2 Ns
Range 0.5–190.4 0.4–310.0 0.4–310.0
No obs 209 774 983
Patient age at HSCT
Median 55.6 41.7 45.0 <0.001
Range 2.3–74.0 0.9–73.8 0.9–74.0
No obs 209 774 983
Donor age
Median 34.3 38.1 37.1 <0.001
Range 13.1–67.6 13.1–72.3 13.1–72.3
No obs 192 668 880
Karnofsky or Lansky status
Median 90.0 90.0 90.0 Ns
Range 20.0–100.0 40.0–100.0 20.0–100.0
No obs 198 723 921
Categorized karnofsky
>= 90 130 (65.7) 465 (64.3) 595 (64.6) Ns
<= 80 68 (34.3) 258 (35.7) 326 (35.4)
Categorized source: BM+PB in BM group
PB 86 (41.1) 356 (46.0) 442 (45.0) Ns
BM 123 (58.9) 418 (54.0) 541 (55.0)
TBI given
no 145 (69.7) 551 (71.6) 696 (71.2) Ns
yes 63 (30.3) 219 (28.4) 282 (28.8)
Intensity of conditioning regimen
MAC 115 (55.3) 506 (65.5) 621 (63.4) 0.01
RIC 93 (44.7) 266 (34.5) 359 (36.6)
Table 1 (continued)
CMV antibodies in donor Total
(N= 983)
p-value
CMV
seronegative
(N= 209)
CMV
seropositive
(N= 774)
N (%)
N (%) N (%)
Number of haplo-HSCTs per center
Median 2.5 2.5 2.5 Ns
Range 0.2–23.5 0.2–23.5 0.2–23.5
No obs 209 774 983
GvHD prophylaxis
Tacro or CSA±
MMF
192 (91.9) 720 (93.0) 912 (92.8) Ns
Other 17 (8.1) 54 (7.0) 71 (7.2)
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+/R+ and D−/R+ pairs), with an approximate 4:1 ratio.
Baseline data are shown in Table 1. Interestingly, a sig-
nificantly higher patient age, lower donor age, more
reduced-intensity conditionings (RIC) and less complete
remissions at transplant were observed in the D−/R+ group
vs. the D+/R+ one. No other significant differences were
present between the two groups. In addition to PT-Cy, the
GvHD prophylaxis consisted of a calcineurin inhibitor
(Tacrolimus or CsA) in association with Mycophenolate
Mofetil in over 90% of patients, without differences between
the two groups. Anti-thymocyte globulin was also used in n
= 3 patients (0.3% of transplants). To better illustrate the
putative relationship between patient and donor based on their
respective ages, a scatter plot was built (Fig. 1). The plot
identifies three clusters (the donor being a parent, a sibling or
offspring) and shows more D−/R+ pairs when the donor is
likely to be a child. This might explain the higher patient age
and the lower donor age observed in this group, and is in line
with the notion that CMV seropositivity increases with age in
both SCT patients and their donors [15, 16].
Univariate analysis
One-year NRM was 21.3% (95% CI: 18.4-24.8) and 18.8%
(95% CI: 13.8–25.5) in the D+/R+ and D−/R+ groups,
respectively (p= 0.40; Fig. 2a). NRM was not significantly
different after stratification for the conditioning intensity,
with estimates in the D+/R+ and D−/R+ groups of 19.8%
(95% CI: 16.3–24.0) and 15.7% (95% CI: 10.0–24.8),
p= 0.40, after MAC and 24.3% (95% CI: 19.1–30.8)
and 21.7% (95% CI: 14.2–33.2), p= 0.5, after RIC.
No significant interaction was detected between the
donor CMV status and the intensity of conditioning
(p= 0.80).
One-year OS was similar in both groups: 55.1% (95% CI:
50.1–58.0) and 55.7% (95% CI: 48.0–62.8) in the D+ /R+
and D−/R+ groups, respectively (p= 0.50, Fig. 2b). As for
NRM, no significant interaction was detected between the
donor CMV status and the intensity of conditioning with
respect to OS (p= 0.60). Relapse-free survival and relapse
incidence were 46.8% (95% CI: 42.8–50.7) and 47.8% (95%
CI: 40.3–54.9), p= 0.40, and 29.9% (95% CI: 26.4–33.8) and
30.8% (95% CI: 24.6–38.7), p= 0.80, at one year after haplo-
HSCT; overall acute and chronic GvHD were 28.5% and
26.3% (p= 0.2), and 27.7% and 29.7% (p= 0.7) respec-
tively, with comparable proportions of severity between the
groups: acute grade 2–4 was 58% and 47% of all graded acute
GvHD events (p= 0.07 by chi-square), acute grade 3-4 was
20% and 20% (p= 1.00) and extensive chronic GvHD was
40% and 33% (p= 0.51) of all graded chronic GvHD events
in the D+/R+ and D–/R+ groups, respectively. Neutrophil
engraftment at 30 days was higher in the D-/R+ group: 91.1
vs. 85.5%, p= 0.01.
Multivariate analysis
Multivariate analysis for NRM confirmed no statistically
significant association with donor CMV serological status
but there was a trend towards a higher NRM using a CMV-
positive donor (Hazard Ratio, HR: 1.45, 95% CI:
0.97–2.17, p= 0.07). Results did not significantly change
when the model was built with either the adjustment for
donor age or the insertion of the variable “relationship
between patient and donor” in replacement of both patient
and donor age (data not shown). The other significant
variables associated with NRM were: patient age, perfor-
mance status and center activity.
Similarly, the donor CMV serological status was not
significantly associated with OS, whereas the significant
variables were: disease status at transplant, performance
status and center activity. Results from the uni- and multi-
variate analysis are shown in Table 2.
Finally, the interaction test for both NRM and OS
between patient-donor relationship and donor CMV status
was not significant, meaning that the lack of significant
association between donor CMV status and outcome is
valid for all the three subgroups shown in Fig. 1.
The observed unexpected difference in neutrophil
engraftment was a posteriori investigated with a multi-
variate model confirming the independent impact of donor
CMV serostatus (p= 0.03), warranting further investigation
in separate studies.
CMV seronegative patients
In the same period, a total of 237 CMV-negative patients
received a non T-cell depleted haplo-HSCT with PT-Cy for
acute leukemia and survival analysis shows 1-y OS=
56.3% (95% CI: 48.3–63.4) and 1-y NRM= 17.7% (95%
CI: 12.8–24.3) for the whole cohort. When analysed sepa-
rately according to the donor CMV serological status, no
significant differences were observed (p= 0.60 for OS, p=
0.50 for NRM) and, similarly, OS and NRM were not
significantly different among CMV-positive and CMV-
negative patients (p= 0.30 for OS, p= 0.20 for NRM).
Discussion
We found similar outcomes using a CMV-positive or a
CMV-negative donor on this registry-based cohort of 983
consecutive CMV-positive patients affected by acute leu-
kemia and receiving a first non T-cell depleted haplo-HSCT
with PT-Cy. Due to the increase of haplo-HSCT activity in
recent years, thanks to the introduction of PT-Cy [9, 17],
these results are relevant and add a piece of information to
the puzzle of the available criteria for the search of the best
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haploidentical donor. Indeed, whereas the donor CMV
serological status has shown to be one of the most important
determinants of patient outcome after transplantation from
an unrelated donor (URD) [1, 4], this has not been inves-
tigated for the most recent platform of non T-cell depleted
haplo-HSCT using PT-Cy. Since physicians could face with
multiple available family haploidentical donors, we believe
that the question of how the donor CMV serostatus may
contribute to the final choice of the donor is a relevant as
well as practical topic. Here we found similar NRM and OS
for the D+/R+ and D−/R+ pairs, indicating that the choice
of a CMV-positive or negative donor led to comparable
outcomes, with a median follow-up of 1.6 years from haplo-
HSCT. In the previous EBMT analysis of donor serostatus
influence on outcome, almost 9000 patients undergoing
URD HSCT were included [1] and we cannot exclude that a
study on haplo-HSCT and PT-Cy using a larger population
might have detected an impact of donor serostatus. It is
unknown if the same conclusions might be applicable for
other diseases (e.g., lymphoma), and a separate analysis or
an implementation of the present one by the integration of
data from other diseases would be useful to answer this
question.
A possible explanation of the results lies in the char-
acteristics of GvHD prophylaxis and of the immune
reconstitution after non T-cell depleted haplo-HSCT with
PT-Cy [18], which is different from what is generally seen
in the URD setting, where a more extensive and prolonged
immune suppression is often present, due to the frequent
use of in vivo T-cell depletion [4, 19] and/or to a higher
incidence of GvHD compared with non T-cell depleted
haplo-HSCT and PT-Cy [20, 21], leading to the adminis-
tration of additional immune-suppressive treatments. Here
we did not observe a detrimental impact of a CMV mis-
match between patient and donor and this might reflect
more favorable immunological conditions after transplant,
compared with the unrelated setting. As an additional
observation, the low incidence of severe chronic GvHD
after non T-cell depleted haplo-HSCT and PT-Cy [22] is
likely to account, at least in part, for the observed results.
Importantly, the lack of a significant association between
the donor CMV serostatus and outcome was confirmed
irrespectively of the conditioning regimen, and this is worth
noting because of the well-known association between the
intensity of conditioning and transplant mortality [23].
The use of PT-Cy has been reported also in the HLA-
matched, related or unrelated setting, initially by the same
authors from Baltimore [24] and thereafter by other groups
[25–29]. To our knowledge, the impact of CMV serostatus
has not been elucidated in this type of transplant platforms
and deserves to be explored, giving the increasing use of
PT-Cy in the HLA-matched setting, too.
We acknowledge some limitations, such as the retro-
spective nature of the analysis, and the lack of some rele-
vant variables currently used for the choice of donor, such
as the AB0-blood group matching [30, 31], or the body
Donor’s age (years )
Donor Old CMV- Intermediate CMV- Young CMV-
Young CMV+Intermediate CMV+Old CMV+
Patient’s age (years)
80
70
60
50
40
30
20
10
10 20 30 40 50 60 70 800
Fig. 1 Putative patient-donor relationship based on the difference in age between the patient and the respective donorEach point represents a
transplant that is located in the graph according to both the patient and the donor age. All transplants clustered into three subgroups, after the
definition of a 18-years difference as the best cut–off: 1) the donor being> 18-years older than the patient (likely to be a parent; upper left); 2) the
donor being> 18-years younger than the patient (likely to be a child-adolescent; lower right); 3) the donor age being less than 18-years older and
less than 18-years younger (likely to be a sibling or even a cousin; middle). More CMV-negative donors are present in the subgroup 2), possibly
explaining the higher patient age, the younger donor age and the use of more RIC among the D−/R+ pairs (see Table 1). Coefficients of
correlation are shown here: donor old (r= 0.87, p< 0.0001; Coeff= 0.853, SD 0.0346, p< 0.0001), donor intermediate (r= 0.86, p< 0.0001;
Coeff= 0.804, SD 0.0255, p< 0.0001), donor young (r= 0.75, p< 0.0001; Coeff= 0.725, SD 0.0359, p< 0.0001) (Color figure online)
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weight [32]. The unexpected finding of a higher NRM after
a CMV-matched donor in multivariate analysis might be
explained by the potential threat represented by the intro-
duction of a second CMV strain from the donor in the
absence of T cells, or by the notion of the immune senes-
cence that is associated with CMV seropositivity [33],
although these speculations should be further confirmed. As
a consequence, caution is needed when interpreting the
multivariate results since, although the donor age has been
adequately taken into account, other, unknown or non-
evaluated variables may actually have affected the out-
comes or some confounding factors may have been
underestimated. The descriptive and comparative data on
CMV-negative patients treated in the same period suggest
that their outcome is not significantly different, however,
any conclusion may be premature at this stage, due to the
relatively low numbers (n= 237). As a final consideration,
we cannot exclude that a difference of less than 11%
exists between the two CMV groups and it has not been
detected here because of the size of the study cohort,
therefore the question might benefit from a larger cohort
analysis.
Nevertheless, this is the first large study addressing this
specific topic and the results suggest that the choice of a
CMV-mismatched donor does not have a detrimental effect
on the patients outcome after haplo-HSCT. This result was
confirmed for both RIC and MAC, and also for the three
subgroups shown in Fig. 1, when the donor is likely to a
parent (left), a sibling (occasionally a cousin; middle) and a
child (right), respectively. A very recent analysis, investi-
gating several variables in the context of AML/MDS
patients receiving haplo-HSCT with the aim of building a
predictive model, did not find donor CMV serostatus as a
predictor of outcome [34], in line with our findings. Like-
wise, recipient CMV serostatus and CMV matching have
been evaluated as a covariates in other series of haplo-
HSCT with PT-Cy [10, 20, 35] and the matching did not
significantly impact on outcomes, although these studies
were not specifically designed for that and lower transplant
numbers were analysed.
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Fig. 2 Non relapse mortality a
and Overall Survival b for D+
/R+ vs. D−/R+ pairs (Color
figure online)
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Importantly, here the advantage of using data from the
registry lies in the ability to capture the data from real-life
across the EBMT centers, thus showing a picture of what is
currently done in clinical practice and what the outcomes
are. As stated previously, we believe the results are worthy
of note, given the increasing number of haplo-HSCTs and
of the number of EBMT centers performing haplo-HSCTs
[36]. Similarly to another recent EBMT report [22], a center
effect has been observed for both NRM and OS (see
Table 2).
In conclusion, after a median follow-up of 1.6 years
from transplant, the choice of a CMV-negative donor
did not impair the outcome of CMV-positive acute
leukemia patients after a first, non T-cell depleted haploi-
dentical HSCT and PT-Cy among this series of almost
one thousand, consecutive patients. Future directions may
focus on the assessment of the hierarchy of all the donor
variables as well as the inclusion of diseases other than
leukemia.
Table 2 Uni-variate and multivariate analysis on NRM and OS. In bold are p-values <0.05.
Non relapse mortality Overall survival
Univariate Multivariate Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
CMV serological status
D−/R+ pairs 1 0.37 1 0.07 1 0.4603 0.1757
D+/R+pairs 1.19 (0.81–1.72) 1.45 (0.97–2.17) 1.09 (0.87–1.40) 1.18 (0.92–1.49)
Patient gender
Male 1 0.156 ns
Female 1.24 (0.92–1.67)
Donor gender
Male 1 0.0865 1 0.1017
Female 0.76 (0.56–1.04) 0.86 (0.71–1.03)
Age at HSCT
10 year increment 1.51 (1.05–1.26) 0.0019 1.16 (1.06–1.27) 0.002 ns
Disease stage at transplant
CR 1 0.0023 1 <.0001 <.0001
no CR 1.62 (1.19–2.22) 2.44 (2.02–2.94) 2.09 (1.70–2.57)
Karnofsky or Lansky status
Increment of 10 points 0.72 (0.65–0.79) <0.0001 0.71 (0.64–0.79) <0.0001 0.76 (0.71–0.81) <.0001 0.82 (0.76–0.88) <.0001
Stem cell source
PB ns 1 0.1755
BM 0.88 (0.73–1.06)
TBI
Yes 1 0.1127 ns
No 1.33 (0.94–1.90)
Conditioning regimen
MAC 1 0.0856 1 0.0238
RIC 1.30 (0.96–1.77) 1.24 (1.03–1.50)
Number of SCT (every year)
Increment of 10 0.77 (0.58–1.01) 0.0573 0.72 (0.54–0.96) 0.027 0.80 (0.68–0.94) 0.0075 0.72 (0.60–0.87) 0.0005
GvHD prophylaxis
Tacro or CSA±MMF ns 0.80 (0.57–1.13) 0.1992
Other 1
Relationship patient/donor
Old D/Young R 0.59 (0.38–0.93) 0.0717 ns
Intermediate R/D 0.83 (0.59–1.16)
Young D/Old R 1
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